WM
MCID: WLD007
MIFTS: 61

Waldenstroem's Macroglobulinemia (WM)

Categories: Blood diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Waldenstroem's Macroglobulinemia

MalaCards integrated aliases for Waldenstroem's Macroglobulinemia:

Name: Waldenstroem's Macroglobulinemia 12 15
Waldenstrom Macroglobulinemia 12 52 25 58 29 54 39 17
Macroglobulinemia of Waldenstrom 52 25
Lymphoplasmacytic Lymphoma with Igm Gammopathy 12
Waldenstrom's Macroglobulinaemia 52
Waldenström's Macroglobulinemia 74
Waldenstrom's Macroglobulinemia 25
Waldenström Macroglobulinemia 25
Lymphoplasmacytic Lymphoma 52
Waldenstrom's Syndrome 52
Wm 25

Characteristics:

Orphanet epidemiological data:

58
waldenstrom macroglobulinemia
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (Europe),1-9/100000 (France),1-9/1000000 (United States),1-9/1000000 (United Kingdom),1-9/1000000 (Spain),1-9/100000 (Europe); Age of onset: Elderly; Age of death: elderly;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare haematological diseases


Summaries for Waldenstroem's Macroglobulinemia

Genetics Home Reference : 25 Waldenström macroglobulinemia is a rare blood cell cancer characterized by an excess of abnormal white blood cells called lymphoplasmacytic cells in the bone marrow. This condition is classified as a lymphoplasmacytic lymphoma. The abnormal cells have characteristics of both white blood cells (lymphocytes) called B cells and of more mature cells derived from B cells known as plasma cells. These abnormal cells produce excess amounts of IgM, a type of protein known as an immunoglobulin; the overproduction of this large protein is how the condition got its name ("macroglobulinemia"). Waldenström macroglobulinemia usually begins in a person's sixties and is a slow-growing (indolent) cancer. Some affected individuals have elevated levels of IgM and lymphoplasmacytic cells but no symptoms of the condition; in these cases, the disease is usually found incidentally by a blood test taken for another reason. These individuals are diagnosed with smoldering (or asymptomatic) Waldenström macroglobulinemia. It can be several years before this form of the condition progresses to the symptomatic form. Individuals with symptomatic Waldenström macroglobulinemia can experience general symptoms such as fever, night sweats, and weight loss. Several other signs and symptoms of the condition are related to the excess IgM, which can thicken blood and impair circulation, causing a condition known as hyperviscosity syndrome. Features related to hyperviscosity syndrome include bleeding in the nose or mouth, blurring or loss of vision, headache, dizziness, and difficulty coordinating movements (ataxia). In some affected individuals, the IgM proteins clump together in the hands and feet, where the body temperature is cooler than at the center of the body. These proteins are then referred to as cryoglobulins, and their clumping causes a condition known as cryoglobulinemia. Cryoglobulinemia can lead to pain in the hands and feet or episodes of Raynaud phenomenon, in which the fingers and toes turn white or blue in response to cold temperatures. The IgM protein can also build up in organs such as the heart and kidneys, causing a condition called amyloidosis, which can lead to heart and kidney problems. Some people with Waldenström macroglobulinemia develop a loss of sensation and weakness in the limbs (peripheral neuropathy). Doctors are unsure why this feature occurs, although they speculate that the IgM protein attaches to the protective covering of nerve cells (myelin) and breaks it down. The damaged nerves cannot carry signals normally, leading to neuropathy. Other features of Waldenström macroglobulinemia are due to the accumulation of lymphoplasmacytic cells in different tissues. For example, accumulation of these cells can lead to an enlarged liver (hepatomegaly), spleen (splenomegaly), or lymph nodes (lymphadenopathy). In the bone marrow, the lymphoplasmacytic cells interfere with normal blood cell development, causing a shortage of normal blood cells (pancytopenia). Excessive tiredness (fatigue) due to a reduction in red blood cells (anemia) is common in affected individuals. People with Waldenström macroglobulinemia have an increased risk of developing other cancers of the blood or other tissues.

MalaCards based summary : Waldenstroem's Macroglobulinemia, also known as waldenstrom macroglobulinemia, is related to lymphoplasmacytic lymphoma and mononeuritis multiplex. An important gene associated with Waldenstroem's Macroglobulinemia is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Cyclophosphamide and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are leukemia and lymphoma

Disease Ontology : 12 A lymphoplasmacytic lymphoma characterized by the accumulation of monoclonal cells in the bone marrow and peripheral lymphoid tissues, and associated with the production of serum immunoglobulin M (IgM) monoclonal protein.

NIH Rare Diseases : 52 Waldenstrom macroglobulinemia is a chronic, slow-growing lymphoproliferative disorder . It usually affects older adults and is primarily found in the bone marrow, although lymph nodes and the spleen may be involved. Affected individuals have a high level of an antibody called immunoglobulin M (IgM) in their blood, which can cause thickening of the blood (hyperviscosity). Although some individuals initially do not have symptoms and are diagnosed from routine blood work, common symptoms may include weakness, appetite loss and weight loss. Other symptoms may include peripheral neuropathy , fever, Raynaud's phenomenon , and mental status changes. Hyperviscosity of the blood may cause nosebleeds, headaches, dizziness, and blurring or loss of vision. The cause of the condition is not known but environmental, genetic, and viral factors have been suggested. There have been some reports of familial cases suggesting a genetic predisposition . Treatment is often reserved for those with symptoms and may include various medications including corticosteroids , alkylating agents , biologic response modifiers and purine analogues.

Wikipedia : 74 Waldenström macroglobulinemia (WM), is a type of cancer affecting two types of B cells:... more...

Related Diseases for Waldenstroem's Macroglobulinemia

Diseases related to Waldenstroem's Macroglobulinemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 582)
# Related Disease Score Top Affiliating Genes
1 lymphoplasmacytic lymphoma 34.1 MYD88 MAG CXCR4 CD5 CD40LG BTK
2 mononeuritis multiplex 30.9 MYOM2 MAG CD40LG
3 cryofibrinogenemia 30.6 CD79A CD40LG
4 autoimmune peripheral neuropathy 30.5 MAG CD40LG
5 mononeuropathy 30.5 MYOM2 MAG CD40LG
6 cryoglobulinemia, familial mixed 30.5 CD5 CD40LG
7 bone lymphoma 30.5 CD79A CD5
8 polyclonal hypergammaglobulinemia 30.4 TNFSF13B MYOM2 CD40LG
9 gamma heavy chain disease 30.4 SDC1 MYD88 IGHV4-38-2 CD40LG
10 toxoplasmosis 30.3 MYD88 CD79A CD40LG
11 prolymphocytic leukemia 30.3 CD5 CD38 CD19
12 richter's syndrome 30.3 IGHV4-38-2 CD5 CD38
13 heavy chain disease 30.3 MYOM2 MYD88 CD79A CD40LG
14 purpura 30.2 TNFSF13B CD79A CD40LG
15 chronic graft versus host disease 30.2 TNFSF13B CD79A
16 central nervous system lymphoma 30.2 TNFSF13B MYD88 CXCR4
17 chickenpox 30.2 CD40LG CD27 CD19
18 monoclonal paraproteinemia 30.1 SDC1 IGHV4-38-2 CD79A CD40LG
19 gastrointestinal lymphoma 30.1 CD79A CD5
20 cerebral lymphoma 30.1 MAG CD79A CD40LG CD19
21 syphilis 30.1 CD79A CD40LG B2M
22 guillain-barre syndrome 30.1 MAG CD79A CD40LG
23 celiac disease 1 30.1 MYD88 CD79A CD40LG CD19
24 hyperglobulinemic purpura 30.0 TNFSF13B CD40LG CD22
25 hairy cell leukemia 29.9 CD5 CD40LG CD38 CD22
26 bacterial infectious disease 29.9 MYD88 IRAK1 CD40LG BTK
27 agammaglobulinemia 29.9 CD79B CD79A CD40LG CD19 BTK
28 mulchandani-bhoj-conlin syndrome 29.8 CD40LG CD38 CD27 CD19
29 acquired immunodeficiency syndrome 29.8 CD79A CD40LG CD38 B2M
30 intravascular large b-cell lymphoma 29.8 MYD88 CD79B CD5 B2M
31 peripheral nervous system disease 29.8 MYOM2 MAG CD40LG B2M
32 anemia, autoimmune hemolytic 29.7 TNFSF13B IGHV4-38-2 CD5 CD40LG CD19
33 extramedullary plasmacytoma 29.6 SDC1 MYOM2 CD79A CD38 B2M
34 composite lymphoma 29.6 IGHV4-38-2 CD79A CD5 CD22
35 lymphoma 29.5 TNFSF13B MYD88 CXCR4 CD5 CD40LG CD38
36 cryoglobulinemia 29.5 TNFSF13B CD79A CD5 CD40LG CD27
37 macroglobulinemia 29.5 TNFSF13B SYK SDC1 MYD88 CXCR4 CD40LG
38 splenic marginal zone lymphoma 29.4 TRAF3 SYK SDC1 CD5 BTK
39 smoldering myeloma 29.3 SDC1 MYOM2 IGHV4-38-2 CD40LG CD38 B2M
40 agammaglobulinemia, x-linked 29.3 SYK CXCR4 CD79A CD40LG BTK
41 thrombocytopenia due to platelet alloimmunization 29.3 TNFSF13B SYK CD40LG CD19
42 peripheral t-cell lymphoma 29.2 SYK CXCR4 CD5 CD38 CD19
43 plasmacytoma 29.1 CD79B CD79A CD5 CD38 CD27 B2M
44 immunoglobulin alpha deficiency 29.0 TNFSF13B CD79A CD40LG CD27 CD19 BTK
45 autoimmune disease 29.0 TNFSF13B SYK CD79A CD40LG CD22
46 cll/sll 28.7 IGHV4-38-2 CD79B CD79A CD5 CD38 CD22
47 b-cell lymphoma 28.6 TNFSF13B SYK MYD88 CXCR4 CD79B CD5
48 marginal zone b-cell lymphoma 28.6 SDC1 MYD88 IGHV4-38-2 CD79B CD79A CD5
49 plasma cell neoplasm 28.5 SDC1 MYOM2 IGHV4-38-2 CD79A CD5 CD40LG
50 mantle cell lymphoma 28.5 SYK CXCR4 CD5 CD40LG CD19 BTK

Graphical network of the top 20 diseases related to Waldenstroem's Macroglobulinemia:



Diseases related to Waldenstroem's Macroglobulinemia

Symptoms & Phenotypes for Waldenstroem's Macroglobulinemia

Human phenotypes related to Waldenstroem's Macroglobulinemia:

58 31 (show all 46)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 leukemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0001909
2 lymphoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0002665
3 monoclonal immunoglobulin m proteinemia 58 31 hallmark (90%) Very frequent (99-80%) HP:0005508
4 gingival bleeding 58 31 frequent (33%) Frequent (79-30%) HP:0000225
5 pallor 58 31 frequent (33%) Frequent (79-30%) HP:0000980
6 respiratory insufficiency 58 31 frequent (33%) Frequent (79-30%) HP:0002093
7 vertigo 58 31 frequent (33%) Frequent (79-30%) HP:0002321
8 abnormality of neutrophils 58 31 frequent (33%) Frequent (79-30%) HP:0001874
9 hypercoagulability 58 31 frequent (33%) Frequent (79-30%) HP:0100724
10 normocytic anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001897
11 hearing impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0000365
12 splenomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0001744
13 hepatomegaly 58 31 occasional (7.5%) Occasional (29-5%) HP:0002240
14 malabsorption 58 31 occasional (7.5%) Occasional (29-5%) HP:0002024
15 reduced consciousness/confusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0004372
16 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
17 renal insufficiency 58 31 occasional (7.5%) Occasional (29-5%) HP:0000083
18 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
19 cranial nerve paralysis 58 31 occasional (7.5%) Occasional (29-5%) HP:0006824
20 ataxia 58 31 occasional (7.5%) Occasional (29-5%) HP:0001251
21 peripheral neuropathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0009830
22 congestive heart failure 58 31 occasional (7.5%) Occasional (29-5%) HP:0001635
23 urticaria 58 31 occasional (7.5%) Occasional (29-5%) HP:0001025
24 pulmonary infiltrates 58 31 occasional (7.5%) Occasional (29-5%) HP:0002113
25 gastrointestinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0002239
26 memory impairment 58 31 occasional (7.5%) Occasional (29-5%) HP:0002354
27 anorexia 58 31 occasional (7.5%) Occasional (29-5%) HP:0002039
28 proptosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000520
29 purpura 58 31 occasional (7.5%) Occasional (29-5%) HP:0000979
30 stroke 58 31 occasional (7.5%) Occasional (29-5%) HP:0001297
31 periorbital edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0100539
32 epistaxis 58 31 occasional (7.5%) Occasional (29-5%) HP:0000421
33 migraine 58 31 occasional (7.5%) Occasional (29-5%) HP:0002076
34 vasculitis 58 31 occasional (7.5%) Occasional (29-5%) HP:0002633
35 cutis marmorata 58 31 occasional (7.5%) Occasional (29-5%) HP:0000965
36 lymphadenopathy 58 31 occasional (7.5%) Occasional (29-5%) HP:0002716
37 pedal edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0010741
38 retinal hemorrhage 58 31 occasional (7.5%) Occasional (29-5%) HP:0000573
39 recurrent infections 58 31 occasional (7.5%) Occasional (29-5%) HP:0002719
40 pleural effusion 58 31 occasional (7.5%) Occasional (29-5%) HP:0002202
41 diarrhea 58 31 occasional (7.5%) Occasional (29-5%) HP:0002014
42 elevated erythrocyte sedimentation rate 58 31 occasional (7.5%) Occasional (29-5%) HP:0003565
43 multifocal epileptiform discharges 58 31 occasional (7.5%) Occasional (29-5%) HP:0010841
44 cryoglobulinemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0100778
45 abnormal retinal vascular morphology 31 occasional (7.5%) HP:0008046
46 abnormality of the retinal vasculature 58 Occasional (29-5%)

GenomeRNAi Phenotypes related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CD22 CD27 CD5 CD79A MAG MYD88

MGI Mouse Phenotypes related to Waldenstroem's Macroglobulinemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.28 B2M BTK CD19 CD22 CD27 CD38
2 cellular MP:0005384 10.21 B2M BTK CD19 CD22 CD27 CD38
3 immune system MP:0005387 10.11 B2M BTK CD19 CD22 CD27 CD38
4 homeostasis/metabolism MP:0005376 10.07 B2M BTK CD19 CD38 CD40LG CD79A
5 neoplasm MP:0002006 9.5 B2M BTK CD19 CD79A CXCR4 MYD88
6 renal/urinary system MP:0005367 9.17 CD19 CD40LG CD79A CXCR4 MYD88 SYK

Drugs & Therapeutics for Waldenstroem's Macroglobulinemia

Drugs for Waldenstroem's Macroglobulinemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 305)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
2
Lenograstim Approved, Investigational Phase 4 135968-09-1
3
Thiotepa Approved, Investigational Phase 4 52-24-4 5453
4 Alkylating Agents Phase 4
5 Orange Approved Phase 3
6
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
7
Chlorambucil Approved Phase 3 305-03-3 2708
8
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
9
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
10
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
11
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
14
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
15
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
16
Morphine Approved, Investigational Phase 3 57-27-2 5288826
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
19
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
20
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
21
Tazobactam Approved Phase 3 89786-04-9 123630
22
Vancomycin Approved Phase 3 1404-90-6 14969 441141
23
Piperacillin Approved Phase 3 66258-76-2 43672
24
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
25
Zanubrutinib Approved, Investigational Phase 3 1691249-45-2
26
Idelalisib Approved Phase 3 870281-82-6
27
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
28
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
29 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
30 Anesthetics, Dissociative Phase 3
31 Anti-Infective Agents Phase 3
32 Antiemetics Phase 3
33 Anti-Bacterial Agents Phase 3
34 Gastrointestinal Agents Phase 3
35 Antifungal Agents Phase 3
36 Etoposide phosphate Phase 2, Phase 3
37 Hematinics Phase 3
38 Neurotransmitter Agents Phase 3
39 Psychotropic Drugs Phase 3
40 Adjuvants, Immunologic Phase 3
41 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
42 Antiparasitic Agents Phase 3
43 Antiprotozoal Agents Phase 3
44 Analgesics Phase 3
45 Cola Phase 3
46 Liver Extracts Phase 3
47 Analgesics, Opioid Phase 3
48 Anti-Anxiety Agents Phase 3
49 Antipsychotic Agents Phase 3
50 Epoetin alfa Phase 3 113427-24-0

Interventional clinical trials:

(show top 50) (show all 507)
# Name Status NCT ID Phase Drugs
1 The Efficacy of Cyclophosphamide Plus Dexamethasone Combinated With Rituximab or Bortezomib for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Randomized Control Trial From China Unknown status NCT02844322 Phase 4 Bortezomib;Rituximab
2 Autologous Stem-cell Transplantation Versus Conventional Chemotherapy for High Risk Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844361 Phase 4
3 The Efficacy of Thalidomide Plus Cyclophosphamide and Dexamethasone Following by Thalidomide and Prednisone Maintenance Therapy for the Newly Diagnosed Waldenström Macroglobulinemia - a Prospective Multicentre Phase Ⅳ Trial From China Unknown status NCT02844309 Phase 4 Thalidomide
4 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
5 A Single Arm, Multicenter, Phase 4 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Chinese Subjects With Relapse or Refractory Waldenström's Macroglobulinemia Recruiting NCT04042376 Phase 4 Ibrutinib
6 A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease) Unknown status NCT00003924 Phase 3
7 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
8 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
9 A Randomised Trial of Chlorambucil Versus Fludarabine as Initial Therapy of Waldenström's Macroglobulinaemia and Splenic Lymphoma With Villous Lymphocytes Completed NCT00608374 Phase 3 chlorambucil;fludarabine phosphate
10 iNNOVATE Study: A Randomized, Double-Blind, Placebo- Controlled, Phase 3 Study of Ibrutinib or Placebo in Combination With Rituximab in Subjects With Waldenström's Macroglobulinemia Completed NCT02165397 Phase 3 Ibrutinib;Placebo;Rituximab
11 Randomized Trial Comparing the Efficacy of Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia,Lymphoplasmacytic Lymphoma or Splenic Marginal Zone Lymphoma Completed NCT00566332 Phase 3 Chlorambucil;Fludarabine
12 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.A Multicentre, Phase III Randomized Study by the PLRG. Completed NCT00801281 Phase 3 Rituximab;Cyclophosphamide;Doxorubicin;Vincristine;Prednisone 1;Prednisone 2
13 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
14 A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies Completed NCT00075478 Phase 3 Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine
15 A Randomized Multicentre Study Comparing G-CSF Mobilized Peripheral Blood and G-CSF Stimulated Bone Marrow in Patients Undergoing Matched Sibling Transplantation for Hematologic Malignancies Completed NCT00438958 Phase 3
16 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
17 The Effects of Procrit (Epoetin Alfa) on Hemoglobin Symptom Distress and Quality of Life During Chemotherapy in Lymphoma Patients With Mild to Moderate Anemia A Multicenter Trial Completed NCT00003341 Phase 3
18 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
19 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Completed NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
20 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
21 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
22 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
23 Vancomycin Versus Placebo in Persistently Febrile Granulocytopenic Patients Given Piperacillin/Tazobactam Completed NCT00003805 Phase 3 piperacillin sodium;piperacillin-tazobactam;tazobactam sodium;vancomycin
24 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
25 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
26 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
27 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
28 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
29 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
30 Efficacy and Safety of Ibrutinib in Patients With Chronic Lymphocytic Leukemia and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Recruiting NCT02991638 Phase 3 Ibrutinib
31 Efficacy of First Line Dexamethasone, Rituximab and Cyclophosphamide (DRC) +/- Bortezomib for Patients With Waldenström's Macroglobulinemia Active, not recruiting NCT01788020 Phase 3 Dexamethasone, Rituximab, Cyclophosphamide;Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib
32 A Phase 3, Randomized, Open-Label, Multicenter Study Comparing the Efficacy and Safety of the Bruton's Tyrosine Kinase (BTK) Inhibitors BGB-3111 and Ibrutinib in Subjects With Waldenström's Macroglobulinemia (WM) Active, not recruiting NCT03053440 Phase 3 BGB-3111;Ibrutinib
33 A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study Enrolling by invitation NCT01804686 Phase 3 PCI-32765 (Ibrutinib)
34 Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1) Not yet recruiting NCT04263480 Phase 3 Carfilzomib + Ibrutinib;Ibrutinib
35 Randomised Phase II/III Study of Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia Not yet recruiting NCT04061512 Phase 2, Phase 3 Dexamethasone, cyclophosphamide, rituximab;Rituximab, ibrutinib
36 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732926 Phase 3 Idelalisib;Rituximab;Bendamustine;Placebo
37 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas Terminated NCT01732913 Phase 3 Placebo;Rituximab;Idelalisib
38 Phase I/II Study to Assess the Safety and Efficacy of Low Doses of Beta LT in Patients With Waldenstrom's Macroglobulinemia Unknown status NCT00041379 Phase 1, Phase 2 beta alethine
39 Study of Safety, Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia Unknown status NCT02981745 Phase 1, Phase 2 CT-1530
40 A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 Unknown status NCT01813227 Phase 2 Carfilzomib;Rituximab;Dexamethasone
41 Velcade/Dexamethasone/Cyclophosphamide(PCD) Versus Rituximab /Dexamethasone/Cyclophosphamide(RCD) for the Treatment of Patients With Waldenstrom's Macroglobulinemia Unknown status NCT02971982 Phase 1, Phase 2 rituximab /Dexamethasone/cyclophosphamide;Velcade/Dexamethasone/cyclophosphamide
42 Phase II Study of Combination Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia: A Multicenter Trial of the European Myeloma Network Unknown status NCT01046006 Phase 2 Bortezomib, Rituximab, Dexamethasone
43 A Single Arm, Phase II Study of the Anti-Blys Monoclonal Antibody, Belimumab in Symptomatic Waldenstroms Macroglobulinaemia Unknown status NCT01142011 Phase 2 Belimumab
44 Phase II Study to Evaluate the Safety and Efficacy of the Treatment With Pentostatin, Cyclophosphamide and Rituximab Followed by Rituximab Maintenance in Previously Untreated and Relapsed Patients With Immunocytoma/Morbus Waldenström, B-CLL and Other Indolent B-Cell Lymphomas Unknown status NCT00927797 Phase 2 Cyclophosphamide, Pentostatin, Rituximab
45 Epigenetic Therapy With Valproic Acid, an HDAC Inhibitor, in Refractory/Relapsed Non-Hodgkin Lymphoma, Hodgkin's Disease and CLL Unknown status NCT01016990 Phase 2 valproic acid
46 Myeloblative Therapy With Autologous Hematopoietic Stem Cell Transplantation in Patients With Multiple Myeloma and B-Cell Malignancies Unknown status NCT00003163 Phase 2 cyclophosphamide;melphalan
47 A Phase II Study to Investigate Biological Correlates of Clinical Response to Panobinostat in Haematological Malignancy Unknown status NCT01658241 Phase 2 panobinostat
48 Safety and Efficacy of Sequential Treatment With a Combination of Rituximab, Fludarabine and Cyclophosphamide Followed by Zevalin (Rituximab and Y-Ibritumomab Tiuxetan) - A Phase I/II Study for Treatment of Patients With Relapsed Indolent and Transformed CD20-Positive B-Cell Non-Hodgkin's-Lymphoma Ineligible for High-Dose Chemo(Radio)Therapy Supported by Autologous Peripheral Blood Stem-Cells Unknown status NCT00397800 Phase 1, Phase 2 cyclophosphamide;fludarabine phosphate
49 A Phase II Study of Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia Completed NCT00422656 Phase 2 Perifosine
50 Phase II Study of Combination Rituxan (Rituximab, Mabthera) and Fludarabine Therapy in Lymphoplasmacytic Lymphoma (Waldenstrom's Macroglobulinemia) Completed NCT00020800 Phase 2 fludarabine phosphate

Search NIH Clinical Center for Waldenstroem's Macroglobulinemia

Genetic Tests for Waldenstroem's Macroglobulinemia

Genetic tests related to Waldenstroem's Macroglobulinemia:

# Genetic test Affiliating Genes
1 Waldenstrom Macroglobulinemia 29 MYD88

Anatomical Context for Waldenstroem's Macroglobulinemia

MalaCards organs/tissues related to Waldenstroem's Macroglobulinemia:

40
B Cells, Bone, Bone Marrow, T Cells, Lymph Node, Heart, Spleen

Publications for Waldenstroem's Macroglobulinemia

Articles related to Waldenstroem's Macroglobulinemia:

(show top 50) (show all 279)
# Title Authors PMID Year
1
Waldenstrom's macroglobulinemia in the era of immunotherapy. 61
31960730 2020
2
Clinical Reasoning: Multifocal neuropathies in a patient with Waldenstrom macroglobulinemia and prior borreliosis. 61
32527969 2020
3
Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia. 61
32558607 2020
4
Catastrophic Antiphospholipid Syndrome as the Initial Presentation of Waldenstrom Macroglobulinemia. 61
32532610 2020
5
An unusual case of cutaneous Waldenstrom macroglobulinemia with the MYD88 L265P mutation. 61
32335928 2020
6
Health-related quality of life in Waldenstrom Macroglobulinemia and IgM-related disorders: A single institution experience. 61
31852014 2020
7
Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. 61
32509586 2020
8
Prognostic Factors in Patients with Low-Grade Nonhodgkin Lymphoma. 61
32158088 2020
9
JL1 Antigen Expression on Bone Marrow Lymphoma Cells from Patients With Non-Hodgkin Lymphoma. 61
31432632 2020
10
Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia. 61
31868242 2019
11
What is new in the treatment of Waldenstrom macroglobulinemia? 61
31591468 2019
12
Development of Central Nervous System Vasculitis in a Patient with Waldenstrom Macroglobulinemia: A Rare Presentation with Poor Prognosis. 61
31824806 2019
13
Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later. 61
30993606 2019
14
Bortezomib-based chemotherapy can improve renal and tubular functions in patients with light chain-associated Fanconi syndrome. 61
30511139 2019
15
Distal Ileal Ulcers as Gastrointestinal Manifestation of Waldenstrom Macroglobulinemia. 61
31616739 2019
16
Ibrutinib in the management of Waldenstrom macroglobulinemia. 61
29996737 2019
17
Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies. 61
30485557 2019
18
Waldenstrom macroglobulinemia retinopathy. Waldenstrom and eyes. 61
30679119 2019
19
Evaluation of Serum Free Light Chain in Diagnosis and Monitoring of Plasma Cell Disorders. 61
32421964 2019
20
Waldenström Macroglobulinemia: Unusual Presentation With Cast Nephropathy/Light Chain Tubulopathy. 61
30799965 2019
21
UNUSUAL SEROUS RETINAL DETACHMENT IN A PATIENT WITH WALDENSTROM MACROGLOBULINEMIA: A CASE REPORT. 61
28106626 2019
22
Central Nervous System Involvement by Waldenstrom Macroglobulinemia: A Case Report of the Bing-Neel Syndrome. 61
31001436 2019
23
Bortezomib overcomes the negative impact of CXCR4 mutations on survival of Waldenstrom macroglobulinemia patients. 61
30366921 2018
24
SEROUS MACULAR DETACHMENT ASSOCIATED WITH WALDENSTROM MACROGLOBULINEMIA MANAGED WITH IBRUTINIB: A CASE REPORT AND NEW INSIGHTS INTO PATHOGENESIS. 61
30531550 2018
25
How I treat elderly patients with plasma cell dyscrasias. 61
30568029 2018
26
A Case of Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma With Lung Lesion. 61
30239460 2018
27
Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. 61
30301877 2018
28
Prediction of immunoglobulin M reduction via therapeutic dose of simple plasma exchange and double filtration plasmapheresis using membrane separation in patients with hyperviscosity syndrome caused by Waldenstrom macroglobulinemia. 61
30188580 2018
29
Morphea associated with primary biliary cirrhosis and Waldenstrom macroglobulinemia: Response to rituximab. 61
30246126 2018
30
Soluble PD-1 ligands regulate T-cell function in Waldenstrom macroglobulinemia. 61
30104397 2018
31
Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. 61
29610969 2018
32
[Research Progress on Diagnosis and Treatment of B Cell Chronic Lymphoproliferative Disease--Review]. 61
30111434 2018
33
A safety profile of medications used to treat Waldenström's macroglobulinemia. 61
29768934 2018
34
Waldenstrom macroglobulinemia involving the superior rectus muscle. 61
29780960 2018
35
A Patient with Artifactually Low Serum High Density Lipoprotein Cholesterol Due to Waldenstrom Macroglobulinemia. 61
30181932 2018
36
Patient With 2 Hematologic Malignancies Presenting as Neurolymphomatosis. 61
29465612 2018
37
Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. 61
29203585 2018
38
Case Report of IgM Multiple Myeloma: Diagnosing a Rare Hematologic Entity. 61
29318955 2018
39
Ibrutinib. 61
30069629 2018
40
Carfilzomib as salvage therapy in Waldenstrom macroglobulinemia: a case series. 61
28583038 2018
41
Waldenstrom's Macroglobulinemia: An Update. 61
29326801 2018
42
Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ). 61
27734522 2017
43
The presence of monoclonal gammopathy in Ph-negative myeloproliferative neoplasms is associated with a detrimental effect on outcomes. 61
28482711 2017
44
TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia. 61
28754818 2017
45
A case of Waldenstrom Macroglobulinemia in which intermittent one-day administration cycles of bendamustine were effective for alleviation of nausea and maintenance of remission. 61
28883220 2017
46
Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia. 61
28786474 2017
47
IgM Myeloma with Plasma Cell Leukemia: Case Report and Literature Review. 61
29066491 2017
48
[Clinical features and prognosis of 17 patients with primary cold agglutinin disease]. 61
29081197 2017
49
Significances of MYD88L265P and CXCR4WHIM Mutations in Waldenstrom Macroglobulinemia. 61
28877839 2017
50
EDTA-induced pseudothrombocytosis and citrate-induced platelet agglutination in a patient with Waldenstrom macroglobulinemia. 61
28781833 2017

Variations for Waldenstroem's Macroglobulinemia

Cosmic variations for Waldenstroem's Macroglobulinemia:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM143780282 haematopoietic and lymphoid tissue,lymph node,lymphoid neoplasm,Hodgkin lymphoma c.2209C>A p.Q737K 6:137881155-137881155 4

Expression for Waldenstroem's Macroglobulinemia

Search GEO for disease gene expression data for Waldenstroem's Macroglobulinemia.

Pathways for Waldenstroem's Macroglobulinemia

Pathways related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 TRAF3 TNFSF13B SYK MYD88 IRAK1 CD79B
2
Show member pathways
13.36 SYK MYD88 CD79B CD79A CD40LG CD22
3
Show member pathways
13.34 TNFSF13B SYK MYD88 IRAK1 CXCR4 CD40LG
4
Show member pathways
13.27 TRAF3 TNFSF13B SYK MYD88 IRAK1 CD40LG
5
Show member pathways
13.16 SYK MYD88 IRAK1 CD79B CD79A CD19
6
Show member pathways
12.87 TRAF3 SYK MYD88 IRAK1 CXCR4 B2M
7
Show member pathways
12.77 SYK CXCR4 CD79B CD79A BTK
8 12.73 TRAF3 SYK MYD88 IRAK1 B2M
9
Show member pathways
12.68 TRAF3 SYK MYD88 IRAK1 CD19 BTK
10
Show member pathways
12.65 TRAF3 TNFSF13B MYD88 IRAK1 CD40LG
11
Show member pathways
12.65 SYK CD79B CD79A CD22 CD19 BTK
12
Show member pathways
12.57 SYK CD79B CD79A CD40LG BTK
13
Show member pathways
12.49 SYK CD79B CD79A CD22 CD19 BTK
14
Show member pathways
12.47 TRAF3 TNFSF13B MYD88 IRAK1 CD40LG CD27
15
Show member pathways
12.38 SYK CD22 CD19 BTK
16
Show member pathways
12.27 SYK CD79B CD79A CD22 CD19 BTK
17
Show member pathways
12.21 TRAF3 MYD88 IRAK1 BTK
18 12.06 SDC1 MAG CD40LG CD22
19 12.01 CD40LG CD22 CD19 B2M
20
Show member pathways
11.98 SYK CD79B CD79A BTK
21 11.92 TRAF3 TNFSF13B SYK MYD88 IRAK1 CXCR4
22 11.84 CD5 CD38 CD22 CD19
23 11.81 SDC1 CD79A CD19
24
Show member pathways
11.76 SYK CD79B CD79A CD22 CD19 BTK
25 11.76 SDC1 CD79B CD79A CD5 CD38 CD22
26
Show member pathways
11.74 TNFSF13B CD40LG CD27
27 11.72 TRAF3 SYK MYD88 IRAK1 BTK
28
Show member pathways
11.66 TRAF3 TNFSF13B IRAK1 CD40LG
29
Show member pathways
11.63 MYD88 MAG IRAK1
30 11.52 TRAF3 TNFSF13B SYK MYD88 IRAK1 CD40LG
31 11.48 SDC1 MYD88 CD40LG
32 11.25 CD79A CD40LG CD19 BTK

GO Terms for Waldenstroem's Macroglobulinemia

Cellular components related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016020 10.31 TNFSF13B SYK SDC1 MAG IRAK1 CXCR4
2 integral component of plasma membrane GO:0005887 9.92 SDC1 MAG CD79B CD5 CD40LG CD27
3 plasma membrane GO:0005886 9.89 TNFSF13B SYK SDC1 MYD88 MAG IRAK1
4 protein-containing complex GO:0032991 9.85 SYK SDC1 MYD88 IRAK1 CXCR4 CD19
5 cell surface GO:0009986 9.8 SDC1 CXCR4 CD40LG CD38 CD27 CD22
6 membrane raft GO:0045121 9.73 MAG CD79A CD19 BTK
7 external side of plasma membrane GO:0009897 9.36 SDC1 IGHV4-38-2 CXCR4 CD79B CD79A CD5
8 B cell receptor complex GO:0019815 9.33 SYK CD79B CD79A

Biological processes related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.23 TRAF3 TNFSF13B MYD88 IRAK1 CXCR4 CD79B
2 negative regulation of apoptotic process GO:0043066 10.02 MYD88 IRAK1 CD40LG CD38 CD27
3 immune response GO:0006955 10.01 TNFSF13B CXCR4 CD79B CD40LG B2M
4 adaptive immune response GO:0002250 9.98 SYK CD79B CD79A CD19 BTK
5 cell surface receptor signaling pathway GO:0007166 9.88 SYK MYD88 CD79B CD79A CD27
6 innate immune response GO:0045087 9.87 TRAF3 SYK MYD88 IRAK1 IGHV4-38-2 BTK
7 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.85 MYD88 IRAK1 CD40LG BTK
8 positive regulation of JNK cascade GO:0046330 9.79 TRAF3 MYD88 CD27
9 B cell differentiation GO:0030183 9.78 CD79B CD79A CD40LG
10 negative regulation of neuron projection development GO:0010977 9.77 MAG CD38 B2M
11 apoptotic signaling pathway GO:0097190 9.77 CD5 CD38 BTK
12 regulation of immune response GO:0050776 9.77 TNFSF13B CD40LG CD22 CD19 B2M
13 tumor necrosis factor-mediated signaling pathway GO:0033209 9.76 TRAF3 TNFSF13B CD40LG CD27
14 positive regulation of type I interferon production GO:0032481 9.74 SYK MYD88 IRAK1
15 T cell costimulation GO:0031295 9.73 TNFSF13B CD5 CD40LG
16 toll-like receptor signaling pathway GO:0002224 9.71 TRAF3 MYD88 IRAK1
17 response to interleukin-1 GO:0070555 9.67 MYD88 IRAK1 CD38
18 immune system process GO:0002376 9.65 TRAF3 TNFSF13B SYK MYD88 IRAK1 CD79B
19 toll-like receptor 9 signaling pathway GO:0034162 9.63 MYD88 IRAK1
20 B cell activation GO:0042113 9.61 CD79A CD22 BTK
21 Toll signaling pathway GO:0008063 9.58 TRAF3 MYD88
22 MyD88-dependent toll-like receptor signaling pathway GO:0002755 9.58 MYD88 IRAK1 BTK
23 cellular response to molecule of fungal origin GO:0071226 9.52 SYK BTK
24 immunoglobulin secretion GO:0048305 9.51 TNFSF13B CD40LG
25 immunoglobulin mediated immune response GO:0016064 9.43 MYD88 CD27 CD19
26 positive regulation of B cell differentiation GO:0045579 9.33 SYK CD27 BTK
27 B cell receptor signaling pathway GO:0050853 9.17 SYK IGHV4-38-2 CD79B CD79A CD38 CD19

Molecular functions related to Waldenstroem's Macroglobulinemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.65 TNFSF13B SYK MYD88 MAG CD22
2 identical protein binding GO:0042802 9.28 SDC1 MYD88 IRAK1 CXCR4 CD79B CD79A
3 Toll-like receptor binding GO:0035325 9.16 SYK MYD88
4 tumor necrosis factor receptor binding GO:0005164 9.13 TRAF3 TNFSF13B CD40LG

Sources for Waldenstroem's Macroglobulinemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....